Denise ScotsKnight - Mereo Biopharma CEO, Co-Founder, Executive Director

MREO
 Stock
  

USD 0.86  0.02  2.27%   

  CEO
Dr. Denise ScotsKnight is Chief Executive Officer, CoFounder, Executive Director of the Company. Prior to Mereo, she led Phase4 Partners management buyout from Nomura in 2010, becoming Phase4 Partners managing partner. Prior to becoming a VCist, she was in research and development management at Amersham and Fisons and a senior executive at Scientific Generics. At Nomura, she became managing director after leading the life science investment team. Prior to Nomura, she was an investment manager at Rothschild Asset Management. She is chairman of Nabriva Therapeutics AG and a board member of OncoMed Pharmaceuticals, Inc., and Albireo Limited. She has served on many European and U.S. private and public company boards, including Idenix Pharmaceuticals, Inc. . Dr ScotsKnight has a PhD and BSc from Birmingham University and was a Fulbright scholar at the University of California Berkeley.
    Ph.D    
44 33 3023 7300  https://www.mereobiopharma.com

Mereo Biopharma Management Efficiency

Mereo Biopharma Group has return on total asset (ROA) of (13.82) % which means that it has lost $13.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 34.85 %, meaning that it created $34.85 on every $100 dollars invested by stockholders. Mereo Biopharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 16.76 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Mereo Biopharma Group has a current ratio of 7.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Mereo Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mereo Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mereo Biopharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mereo to invest in growth at high rates of return. When we think about Mereo Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

CEO Since

Pascal PerrierBurberry
2013
Nicolas BosPagnie Financiere RI
2017
Bernard FornasPagnie Financiere RI
2016
Cyrille VigneronPagnie Financiere RI
2016
Jerome LambertPagnie Financiere RI
2018
JeanChristophe BedosBirks Group
2012
Christopher BaileyBurberry
N/A
Richard LepeuPagnie Financiere RI
2017
Daniel RiedoPagnie Financiere RI
2014
Marco GobbettiBurberry
2017
Philippe LeopoldMetzgerPagnie Financiere RI
2012
Georges KernPagnie Financiere RI
2012
Christopher LapuenteLvmh Moet Henn
2011
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. Mereo Biopharma Group (MREO) is traded on NASDAQ Exchange in USA and employs 49 people.

Mereo Biopharma Group Leadership Team

Elected by the shareholders, the Mereo Biopharma's board of directors comprises two types of representatives: Mereo Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mereo. The board's role is to monitor Mereo Biopharma's management team and ensure that shareholders' interests are well served. Mereo Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mereo Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Peter Bains, Non-Executive Independent Director
Kunal Kashyap, Non-Executive Director
Deepa Pakianathan, Non-Executive Director
Paul Blackburn, Non-Executive Independent Director
Alastair MacKinnon, Chief Medical Officer and Co-Founder
Michael Wyzga, Non-Executive Director
Richard Jones, CFO, Executive Director
Richard Francis, Head of Pharmaceutical Development
John Richard, Head of Corporate Development and Co-Founder
Charles Sermon, Co-Founder, General Counsel, Secretary
Denise ScotsKnight, CEO, Co-Founder, Executive Director
Peter Fellner, Independent Non-Executive Chairman of the Board
Anders Ekblom, Non-Executive Independent Director

Mereo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mereo Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Mereo Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Mereo Biopharma Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Correlation Analysis. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.